Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633470 | 0.85 | LMNA (0.43) | TSHRMMEKMT2AMAPTALDH1A1 | |
| SCHEMBL13673085 | 0.85 | MEN1 (0.45) | TSHRMMEKMT2AMAPTALDH1A1 | |
| SCHEMBL12107715 | 0.83 | TSHR (0.36) | TSHRMMEKMT2AMAPTALDH1A1 | |
| SCHEMBL10075279 | 0.80 | MAPT (0.39) | TSHRMMEKMT2AMAPTALDH1A1 | |
| SCHEMBL19682077 | 0.80 | TSHR (0.34) | TSHRMMEALDH1A1 | |
| SCHEMBL27269485 | 0.78 | MME (0.37) | TSHRMMEALDH1A1 | |
| SCHEMBL12700464 | 0.77 | MME (0.36) | MMEKMT2AMAPTMEN1 | |
| SCHEMBL13369270 | 0.76 | ADAM17 (0.43) | MMEKMT2AMAPTMEN1 | |
| SCHEMBL12109569 | 0.75 | TSHR (0.33) | TSHR | |
| SCHEMBL2610579 | 0.75 | TSHR (0.33) | TSHRMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | IAPP, GCG, INSR | TSHR 2225/4885MME 488/4885KMT2A 4468/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | TSHR 1869/4885MME 1086/4885KMT2A 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.